Navigation Links
All-Oral Combination Study with PSI-7977 for HCV Genotypes 1, 2 and 3 Initiated
Date:5/26/2011

enotype 1 subjects;
  • PSI-7977 400mg QD and BMS-790052 60mg QD for 24 weeks in genotype 2 or 3 subjects;
  • PSI-7977 400mg QD, BMS-790052 60mg QD and ribavirin for 24 weeks in genotype 1 subjects;
  • PSI-7977 400mg QD, BMS-790052 60mg QD and ribavirin for 24 weeks in genotype 2 or 3 subjects.

  • Additional details can be found at www.clinicaltrials.gov.

    About Pharmasset

    Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. Our research and development efforts are focused on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have three clinical-stage product candidates advancing in trials in various populations. Our pyrimidine, PSI-7977, an unpartnered uracil nucleotide analog, is currently under study in three Phase 2b trials in patients with HCV genotypes 1 through 6, including abbreviated duration interferon and interferon-free regimens. Our purine, PSI-938, an unpartnered guanosine nucleotide analog, recently reported safety and efficacy data from 14-days of monotherapy as well as 14 days in combination with the pyrimidine, PSI-7977. An SVR-endpoint study of the purine-pyrimidine combination is anticipated to begin third quarter 2011. Mericitabine (RG7128) continues in two Phase 2b trials and one interferon-free trial conducted through a strategic collaboration with Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    Office: +1 (609) 865-0693

    Forward-Looking Statements

    Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform
    '/>"/>

    SOURCE Pharmasset, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
    2. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
    3. Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study
    4. ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor
    5. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
    6. Particle Sciences and Celanese EVA Performance Polymers Collaborate to Accelerate Drug-Eluting Device Combinations
    7. Jennerex and Green Cross Announce Publication of Positive Clinical Data of JX-594 in Combination With Sorafenib in Advanced Liver Cancer
    8. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
    9. New Interim Data About Combination Oral Contraceptives
    10. Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
    11. Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/1/2014)... ST. LOUIS , Oct. 1, 2014  Express ... its two nationally available 2015 Express Scripts Medicare ® ... retail pharmacy network featuring Walgreens (NYSE: WAG ... obtain more value, choice and clinical support  for their ... the Express Scripts Medicare Value or ...
    (Date:10/1/2014)... SAN JOSE, Calif. , Oct. 1, 2014  SI-BONE, ... the iFuse Implant System, ® a minimally invasive surgical ... sacroiliac (SI) joint, today announced the expansion of its European ... of Mr. Eric Schaber as General Manager, Germany.  ... , currently vice president of Europe , ...
    (Date:10/1/2014)... Suisse, October 1, 2014 ... dans le domaine de l,analyse des données issues ... une solution de diagnostic in vitro (IVD) du ... complète de la mucoviscidose dans un seul essai ... caractériser tous les types de variantes par l,intermédiaire ...
    Breaking Medicine Technology:Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 3SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 4Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 2Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 3
    ... 2011 BioMedix™, a leader in providing integrated Health ... a U.S. Patent recognizing its innovative solutions and methods ... On July 19, 2011, the United States Patent & ... and Method for Testing for Cardiovascular Disease," crediting BioMedix™ ...
    ... 2011 On the 1-year anniversary of Congress approving ... of Columbia Patients, Cooperative (DCPC), a District-based non-profit organization ... Americans for Safe Access, will hold a press conference ... of the John A. Wilson Building, 1350 Pennsylvania Ave. ...
    Cached Medicine Technology:BioMedix™ Receives Patent for Its Innovative Collaborative Care Business Method 2DC Patients' Cooperative to Announce Operations Hiatus Until City Shows Leadership 2
    (Date:10/1/2014)... Physical Sciences Research Council (EPSRC) will focus on ... systems which run, for example, manufacturing plants, power ... , The research will help understand and ... systems behind our critical national infrastructure. , ... (RITICS), based at Imperial College London, is co-ordinating ...
    (Date:10/1/2014)... Marriagelifeinsurance.com has released a new blog post ... , Senior citizens can purchase a joint life ... ones. A joint policy is cheaper, but will only ... , Life insurance can be used to cover important ... purchased online, as the application process is simple and ...
    (Date:10/1/2014)... Oregon (PRWEB) October 01, 2014 Phoseon ... solutions , continues to expand the business worldwide. This ... along with additional capacity for manufacturing efforts. The company ... the last five years and expects this growth to ... LED curing technology gains worldwide adoption. , “We ...
    (Date:10/1/2014)... Hills, California (PRWEB) October 01, 2014 ... expert, Dr. Kathleen Mojas is celebrating 20 years of ... has assisted hundreds of people to achieve greater joy ... an important list of warning signs and suggestions for ... , Dr. Mojas explains: “Believe it or not, ...
    (Date:10/1/2014)... Anti Aging Clinic (AntiAgingClinic.ca), the Greater Toronto Area’s ... is announcing a discounted cost on Botox units, which ... doing this because we want to give as many ... in Toronto,” says Dr. Brian Sieber, founder of Anti ... Clinic, including laser facials, genesis laser facials, chemical ...
    Breaking Medicine News(10 mins):Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2
    ... the Need for Location-Based Mobile Convergence, Solutions for Enterprises by ... ... Winner, SUNNYVALE, Calif., March 13 Agito Networks, Inc., ... a 2008 VON Magazine Innovator Award, which is awarded,to innovative companies that ...
    ... Successful Execution of Partnership Strategy Provides Nearly $450 Million ... Cash and Committed Cash * 2008 Projected Net Operating Loss ... Greater than $450 Million * Conference Call Webcast Thursday, March 13, 08:30 a.m. ... http://www.isispharm.com , CARLSBAD, Calif., March ...
    ... March 13 DKMS is proud to announce that ... Gala" on,Wednesday, May 7th, 2008 at Capitale in New ... to raise money and awareness for DKMS, the,world,s largest ... which has helped facilitate more than 13,000 transplants., ...
    ... its ... 6th FDA approval, CARLSBAD, ... has received FDA approval on its new,over-the-counter light therapy device, Omnilux ... Omnilux New-U has been clinically proven to reduce periorbital wrinkles,and ...
    ... Compromises Are Not Good Enough, WASHINGTON, March 12 ... tightening of the,health-based National Ambient Air Quality Standard for ... but we cannot. The standard announced,today, although an improvement, ... Act. We are unable to celebrate half measures when ...
    ... The Providence,Service Corporation (Nasdaq: PRSC ) today announced ... shares of its common stock on Form S-3,with the ... will file the proposed shelf registration statement immediately,following the ... the Year Ended,December 31, 2007; however, it has no ...
    Cached Medicine News:Health News:Agito Networks Wins the 2008 VON Magazine Innovator Award for Enterprise Mobility 2Health News:Agito Networks Wins the 2008 VON Magazine Innovator Award for Enterprise Mobility 3Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 2Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 3Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 4Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 5Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 6Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 7Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 8Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 9Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 10Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 11Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 12Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 13Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 14Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 15Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 16Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 17Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 18Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 19Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 20Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 21Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 22Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 23Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 24Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 25Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 26Health News:Super Model Cindy Crawford will be Honored at DKMS 'Linked Against Leukemia Gala' on May 7th at Capitale 2Health News:Omnilux New-U(TM) Hand-Held Device Receives FDA Approval 2Health News:Statement of Bernadette Toomey, President and Chief Executive Officer, American Lung Association 2Health News:Statement of Bernadette Toomey, President and Chief Executive Officer, American Lung Association 3Health News:Providence Service Corporation Announces Intent to File a Common Stock Shelf Registration Statement 2
    ... For the quantitative determination ... human serum. Progesterone ... the principle of competitive ... the test specimen and ...
    ... With the introduction of the innovative GenePaint ... a genome-wide scale is much easier. The ... tightly temperature-controlled manner all steps required for ... microscope slide formats. This includes fixing, staining, ...
    ... platelet incubators provide accurate and stable ... incorporated all of the same alarm, ... found in the Labcold BS Blood ... of product security. An independent 7 ...
    The PC4200h is the largest capacity platelet incubator available. It features a built-in agitator with a capacity of 396 random bags (132 apheresis)....
    Medicine Products: